Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial

Lifecare

Bergen, Norway, 27 May 2025 – Lifecare ASA (LIFE), a medtech company developing next-generation Continuous Glucose Monitoring (CGM) technology, is pleased to announce that Professor Simon Nitter Dankel has been appointed as Principal Investigator for its upcoming clinical trial.

Prof. Dankel is a leading expert in metabolic diseases and nutritional biochemistry, with an impressive track record of high-impact research and leadership in clinical trials. He currently heads the Research Unit for Health Surveys (RUHS) at the University of Bergen, which will host the first trial site.

RUHS brings extensive experience in executing clinical and decentralized trials and offers state-of-the-art infrastructure including a metabolic kitchen, biobank collaboration, and GDPR-compliant digital systems for participant management. This partnership sets the stage for robust, high-quality data collection and world-class regulatory standards.

This appointment follows Lifecare’s recent filing for regulatory approval to launch the clinical trial of its innovative CGM implant, marking another key milestone toward CE-marking and commercial launch.

“Engaging Prof. Dankel and RUHS is a strategic move that highlights our commitment to scientific excellence and clinical rigor,” said Joacim Holter, CEO of Lifecare ASA. “Their expertise will be instrumental as we accelerate efforts to bring our transformative technology to people living with diabetes.”

About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Attachments
Lifecare appoints renowned metabolic expert Prof. Simon Dankel as Principal Investigator for upcoming clinical trial

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.